Growing need for prevention of catheter related bloodstream infections

 

Approximately, 250,000 infections, known as catheter related bloodstream infections (CRBSIs), occur in the United States each year – a number that is likely to grow significantly due to:

 

• Increased use of catheters in patients

• Increase use of antibiotics, which may alter the normal body flora, opening niches for the invasion of biofilm formers on the catheter’s surface

• Increasing prevalence of antibiotic resistant bacteria, including multi-drug resistant pathogens identified by the FDA as serious threats to public health

 

Despite these growing risks and escalating costs:

 

• Fewer than 10% of patients with central venous catheters receive any systemic prophylaxis

• No pharmacologic agents have been approved for the prevention of CRBSIs 

 

CorMedix engages Evercore Partners to explore strategic alternatives

 

CorMedix Inc. retains investment bank Evercore as financial advisor to explore strategic alternatives, in order to accelerate the global development of Neutrolin® Catheter Lock Solution and maximize shareholder value. The Company conservatively estimates a multi-billion dollar global market opportunity.

 

CorMedix is actively exploring all options to fund a pivotal Phase 3 study for Neutrolin® in the United States.

 

Please complete the form below for more information about collaboration opportunities with CorMedix: